The DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease
Open accessAbstract
AIMS/HYPOTHESIS: The sodium-glucose cotransporter 2 (SGLT2) inhibitor canagliflozin slows progression of kidney function decline in type 2 diabetes. The aim of this study was to assess the effect of the SGLT2 inhibitor canagliflozin on biomarkers for progression of diabetic kidney disease (DKD). METHODS: A canagliflozin mechanism of action (MoA) network model was constructed based on an in vitro transcriptomics experiment in human proximal tubular cells and molecular features linked to SGLT2 inhibitors from scientific literature. This model was mapped onto an established DKD network model that describes molecular processes associated with DKD. Overlapping areas in both networks were subsequently used to select candidate biomarkers that change with canagliflozin therapy. These biomarkers were measured in 296 stored plasma samples from a previously reported 2 year clinical trial comparing canagliflozin with glimepiride. RESULTS: Forty-four proteins present in the canagliflozin MoA molecular model overlapped with proteins in the DKD network model. These proteins were considered candidates for monitoring impact of canagliflozin on DKD pathophysiology. For ten of these proteins, scientific evidence was available suggesting that they are involved in DKD progression. Of these, compared with glimepiride, canagliflozin 300 mg/day decreased plasma levels of TNF receptor 1 (TNFR1; 9.2%; p < 0.001), IL-6 (26.6%; p = 0.010), matrix metalloproteinase 7 (MMP7; 24.9%; p = 0.011) and fibronectin 1 (FN1; 14.9%; p = 0.055) during 2 years of follow-up. CONCLUSIONS/INTERPRETATION: The observed reduction in TNFR1, IL-6, MMP7 and FN1 suggests that canagliflozin contributes to reversing molecular processes related to inflammation, extracellular matrix turnover and fibrosis. Trial registration ClinicalTrials.gov NCT00968812.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures

![Fig. 2 Canagliflozin MoA model construction. The literature-based MoA core model was constructed based on molecular features extracted from publications on SGLT2 inhibitors as well as from a manuscript on the impact of hyperglycaemia on tubulus cells [18]. The MoA core model (consisting of 74 connected protein-coding genes out of the set of 78) was expanded by deregulated transcripts from the in vitro cell culture experiment in HK2 cells, thus leading to the final canagliflozin MoA molecular model holding 105 protein-coding genes. Up- and downregulated protein-coding genes after canagliflozin treatment in HK2 cells are highlighted in red and green, respectively, in the final canagliflozin MoA molecular model. The intensity of colour indicates the level of up- and downregulation, with darker colours representing the greatest change. Cana, canagliflozin; CTRL, control; HG, high glucose; TX, transcriptomics. MGEA5 is also known as OGA](https://figures.cochat.ai/paper-figures/7844c58ffc3744009fd61e2761300e3e/canagliflozin-reduces-inflammation-and-fibrosis-biomarkers-a-potential-mechanism-figure-2.jpg)





Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Empagliflozin, dapagliflozin, canagliflozin, and ertugliflozin have shown a decrease in hospitalization for HF in their CVOTs.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [444]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Empagliflozin and canagliflozin demonstrated reduction in MACE in CVOTs; empagliflozin also demonstrated decreased CV death and all-cause mortality.”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [444]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In humans, the serum level of IL-6 dropped by 26.6% (p = 0.010) after 2 years of canagliflozin treatment [35].”
From Neuroprotective effect of SGLT2 inhibitors. (2021) · cites this paper as [35]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, recent data support the notion that SGLT2 inhibitors reduce oxidative stress in the kidney by >50% and blunt increases in angiotensinogen as well as reduce NLRP3 inflammasome activity (100,102,103).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [103]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Multiple studies have shown renal and CV benefits of SGLT2is239,424–426,444,1052–1054”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [444]
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes
Wanner, C., Inzucchi, S. E., Lachin, J. M., Fitchett, D., von Eynatten, M., Mattheus, M., Johansen, O. E., Woerle, H. J., Broedl, U. C., & Zinman, B. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1515920 · Cited by 3,655
Levey, A. S., Coresh, J., Greene, T., Marsh, J., Stevens, L. A., Kusek, J. W., Van Lente, F., & for Chronic Kidney Disease Epidemiology Collaboration (2007) · Clinical Chemistry · doi:10.1373/clinchem.2006.077180 · Cited by 1,855
Fox, C. S., Matsushita, K., Woodward, M., Bilo, H. J., Chalmers, J., Heerspink, H. J. L., Lee, B. J., Perkins, R. M., Rossing, P., Sairenchi, T., et al. (2012) · The Lancet · doi:10.1016/s0140-6736(12)61350-6 · Cited by 1,401
Self-citationHeerspink, H. J. L., Perkins, B. A., Fitchett, D. H., Husain, M., & Cherney, D. Z. I. (2016) · Circulation · doi:10.1161/circulationaha.116.021887 · Cited by 1,376
Self-citationKidney disease and increased mortality risk in type 2 diabetes
Afkarian, M., Sachs, M. C., Kestenbaum, B., Hirsch, I. B., Tuttle, K. R., Himmelfarb, J., & de Boer, I. H. (2013) · Journal of the American Society of Nephrology · doi:10.1681/asn.2012070718 · Cited by 1,298
Cefalu, W. T., Leiter, L. A., Yoon, K.-H., Arias, P., Niskanen, L., Xie, J., Balis, D. A., Canovatchel, W., & Meininger, G. (2013) · The Lancet · doi:10.1016/s0140-6736(13)60683-2 · Cited by 724
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Pathogenesis and Treatment of Chronic Kidney Disease: A Review of Our Recent Basic and Clinical Data
Tomino, Y. (2014) · Kidney and Blood Pressure Research · doi:10.1159/000368458 · Cited by 566
Interleukin-6 Signaling Pathway and Its Role in Kidney Disease: An Update
Su, H., Lei, C.-T., & Zhang, C. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00405 · Cited by 524
Cited by
Mechanisms of Cardiovascular Benefits of Sodium Glucose Co-Transporter 2 (SGLT2) Inhibitors
Lopaschuk, G. D., & Verma, S. (2020) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2020.02.004 · Cited by 894
Molecular mechanisms and therapeutic targets for diabetic kidney disease
Tuttle, K. R., Agarwal, R., Alpers, C. E., Bakris, G. L., Brosius, F. C., Kolkhof, P., & Uribarri, J. (2022) · Kidney International · doi:10.1016/j.kint.2022.05.012 · Cited by 668
Pathophysiology of diabetic kidney disease: impact of SGLT2 inhibitors
DeFronzo, R. A., Reeves, W. B., & Awad, A. S. (2021) · Nature Reviews Nephrology · doi:10.1038/s41581-021-00393-8 · Cited by 589
Mechanisms of Cardiorenal Effects of Sodium-Glucose Cotransporter 2 Inhibitors
Zelniker, T. A., & Braunwald, E. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.11.031 · Cited by 566
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Metadata
- Authors
- Heerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G.
- Affiliations
- University Medical Center Groningen (NL)
- Innsbruck Medical University (AT)
- Janssen Research & Development (United States) (US)
- EmergenTec (Austria) (AT)
- Corresponding author
- Heerspink, Hiddo J. L.
- ORCID
- Venue
- Diabetologia
- Published
- 2019-04-17
- Volume
- 62
- Issue
- 7
- Pages
- 1154-1166
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- PMC
- PMC6560022
- OpenAlex
- W2940024069
- Semantic Scholar
- f618f0ee8bdd64eea246f4a3ccbb16c2ab1f7ccc
- Cited by
- 457
- References
- 34
- Citations by year
- 2026: 37 · 2025: 62 · 2024: 61 · 2023: 79 · 2022: 89 · 2021: 79 · 2020: 33 · 2019: 12
- FWCI
- 41.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- Locations
- Diabetologia (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (publishedVersion, cc-by)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
- Funders
- Janssen Research and Development
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Nephrology › Acute Kidney Injury Research
- Keywords
- canagliflozin, SGLT2 inhibitors, diabetic nephropathy, inflammation, renal fibrosis, TNF receptor 1, interleukin-6, matrix metalloproteinase-7, FN1, extracellular matrix turnover, glimepiride, type 2 diabetes, plasma biomarkers, proximal tubular epithelial cells
- MeSH terms
- Canagliflozin, Sodium-Glucose Transporter 2 Inhibitors, Cell Line, Diabetes Mellitus, Type 2, Fibronectins, Fibrosis, Humans, Inflammation, Kidney Diseases, Biomarkers, Interleukin-6, Matrix Metalloproteinase 7, Receptors, Tumor Necrosis Factor, Type I, Renal Insufficiency, Chronic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. https://app.cochat.ai/papers/10.1007/s00125-019-4859-4
- The paper
- Heerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019). Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia. https://doi.org/10.1007/s00125-019-4859-4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.